Q2 2022 13F Holders as of 30 Jun 2022
-
Type / Class
-
Equity / COM
-
Total 13F shares
-
25,769,304
-
Share change
-
-174,173
-
Total reported value
-
$402,774,000
-
Price per share
-
$15.63
-
Number of holders
-
47
-
Value change
-
-$2,773,815
-
Number of buys
-
13
-
Number of sells
-
26
Institutional Holders of Jade Biosciences, Inc. - COM (AVTE) as of Q2 2022
As of 30 Jun 2022,
Jade Biosciences, Inc. - COM (AVTE) was held by
47 institutional
shareholders
that filed Form 13F with the SEC.
Together, they reported ownership of
25,769,304 shares.
The largest 10 holders included
RA CAPITAL MANAGEMENT, L.P., Sofinnova Investments, Inc., Atlas Venture Life Science Advisors, LLC, BAKER BROS. ADVISORS LP, Cormorant Asset Management, LP, CITADEL ADVISORS LLC, TCG Crossover Management, LLC, BlackRock Inc., FMR LLC, and OUP Management Co., LLC.
This page lists
47
institutional shareholders reporting positions in this security
for the Q2 2022 filing period.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price
|
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.